Human Genomic Evidence: Revolutionising the identification and prioritisation of targets for better medicines
Posted 17th October 2018 by Kieran Chambers
Nine out of 10 potential drugs that enter clinical trials never make it to the market. Failure often occurs because the biological target chosen is not well understood. However, it is hard to objectively select targets with a high chance of clinical success because the data required to predict efficacy and safety are complex, dispersed and incomplete. To address this challenge, Open Targets was founded in 2014 as a public-private partnership by GSK, EMBL-EBI and the Wellcome Sanger Institute. The consortium has grown since its launch, welcoming new partners Biogen in 2016, Takeda in 2017, and Celgene in 2018.
Posted 5th September 2018 by Kieran Chambers
I don’t need to tell you that pharma has changed, that it is still changing at speed, or that change is the new normal. I don’t need to tell you because you − more than anyone else − already know. The passing of the blockbuster era has caused uncertainty. Without the superstar drugs of old, where does the industry go next? It’s a serious challenge, but without challenge, there is no change. The answer, of course, is the scalar shift from blockbuster generic to precision medicine specific.
Posted 19th April 2017 by Laura Berry
Over the last decade, there has been a huge shift in the popular perception of microorganisms – instead of considering them as potentially pathogenic organisms that should be destroyed, we now realise that the microorganisms living in and on us are an essential part of us and necessary for good health.